| Date | Product | Disease | Phase | Company | Therapeutic area |
|---|---|---|---|---|---|
| 2016-03-23 | Brilinta® (ticagrelor) | prevention of major vascular events in patients with an acute ischaemic strok | 3 | AstraZeneca (UK) | Cardiovascular diseases |
| 2016-03-23 | AGS-003 | non-small cell lung cancer (NSCLC) | 2 | Argos Therapeutics (USA - NC) | Cancer - Oncology |
| 2016-03-22 | CHIKV-dMAb | chikungunya virus infection | preclinical | Inovio Pharmaceuticals (USA - PA) | Infectious diseases |
| 2016-03-21 | atezolizumab (MPDL3280A) and daratumumab | multiple myeloma | 1b | Genentech, a member of Roche Group (USA - CA - Switzerland) | Cancer - Oncology |
| 2016-03-21 | rigosertib | myelodysplastic syndrome | 3 | Onconova Therapeutics (USA - PA) | Cancer - Oncology |
| 2016-03-19 | PV-10 and pembrolizumab | Stage III locally advanced cutaneous melanoma | 3 | Provectus Pharmaceuticals (USA - TN) | Cancer - Oncology |
| 2016-03-18 | Remsima® (biosimilar infliximab) | inflammatory bowel disease, Crohn’s disease, ulcerative colitis | Celltrion Healthcare (South Korea) | Autoimmune diseases - Inflammatory diseases - Digestive diseases | |
| 2016-03-17 | demcizumab and pembrolizumab | locally advanced or metastatic solid tumors | 1b | OncoMed Pharmaceuticals (USA - CA) Celgene (USA - NJ) | Cancer - Oncology |
| 2016-03-17 | MBX-8025 (2-[4-[[(2R)-2-ethoxy-3-[4-(trifluoromethyl)phenoxy]propyl]thio]-2-methylphenoxy]acetic acid (1:1) lysine dihydrate) | homozygous familial hypercholesterolemia | 2 | Cymabay Therapeutics (USA - CA) | Rare diseases - Genetic diseases - Metabolic diseases |
| 2016-03-16 | Livatag® (doxorubicin Transdrug®) | hepatocellular carcinoma | preclinical | Onxeo (France) | Cancer - Oncology - Rare diseases |
| 2016-03-16 | gerilimzumab | 1 | Bird Rock Bio, previously RuiYi (USA - CA) | Autoimmune diseases – Inflammatory diseases - Rheumatic diseases | |
| 2016-03-16 | AGS-003 | metastatic renal cell carcinoma | 3 | Argos Therapeutics (USA - NC) | Cancer - Oncology |
| 2016-03-16 | oxyntomodulin (MOD-6031) | obesity, type II diabetes | 1 | Opko Health (USA - Fl) | Metabolic diseases |
| 2016-03-16 | VXM01 | metastatic colorectal cancer | 1 | Vaximm (Germany) | Cancer - Oncology |
| 2016-03-16 | pegylated recombinant human hyaluronidase - PEGPH20 In combination With Abraxane® (nab-paclitaxel) and gemcitabine | pancreatic ductal adenocarcinoma | 3 | Halozyme Therapeutics (USA - CA) | Cancer - Oncology |
| 2016-03-16 | Vx-001 | non-small-cell lung cancer | 2b | Vaxon Biotech (France) | Cancer - Oncology |
| 2016-03-16 | EBV-CTL (allogeneic Epstein-Barr virus cytotoxic T lymphocytes) | EBV-associated nasopharyngeal carcinoma | Atara Biotherapeutics (USA - CA) | Cancer - Oncology | |
| 2016-03-15 | IMP321 | melanoma | 1-2a | Prima Biomed (Australia) | Cancer - Oncology |
| 2016-03-15 | PBI-4050 | scleroderma | 2 | ProMetic Life Sciences (Canada) | Autoimmune diseases - Rheumatic diseases |
| 2016-03-14 | yttrium-90- labeled (90Y) clivatuzumab tetraxetan | metastatic pancreatic cancer | 3 | Immunomedics (USA - NJ) | Cancer - Oncology |
